

SJMLS - 10(1) - 027

**Unravelling HIV-1's Immune Evasion: Insights into Persistent Infection, Disease Progression, and Emerging Therapies.**

Abraham Ehinomhen Ubhenin\*<sup>1</sup>, Joshua Onyeka Ikebuiro<sup>2</sup>, Yusuf Nafisat Abdulmalik<sup>3</sup>, Tyem Lawal Danjuma<sup>4</sup>.  
Department of Biochemistry, Faculty of Sciences, Federal University of Lafia, Nasarawa State, Nigeria <sup>1</sup>.  
Department of Molecular Biology, Faculty of Sciences, Wageningen University, Netherlands <sup>2</sup>, Department of  
Biochemistry, Faculty of Basic and Applied Sciences, Osun State University, Osogbo, Osun State, Nigeria <sup>3</sup>,  
Department of Medical Biochemistry, Faculty of Basic Sciences, Federal University Wukari, Nasarawa Taraba  
State, Nigeria <sup>4</sup>

Author for Correspondence \*: ehibram@yahoo.co.uk/+234-813-389-3080.  
<https://dx.doi.org/10.4314/sokjmls.v10i1.27>

**Summary**

HIV remains a significant global public health challenge, with vulnerable populations in regions such as Sub-Saharan Africa, Asia, Eastern Europe, and Latin America bearing a disproportionate burden. This paper explores the latest research on HIV-1's immune evasion strategies, its impact on disease progression, and emerging therapies aimed at finding a cure. Despite advancements in treatment, including antiretroviral therapy (ART) and fixed-dose combination therapies that have made HIV a manageable chronic condition, the virus persists, especially in macrophages, which serve as key reservoirs of infection. HIV-1's pathogenesis is further complicated by its ability to evade the immune system through immune activation, viral evolution, and coreceptor usage, with distinct strains (R5 and X4) influencing disease progression. Macrophages play a critical role in viral replication, contributing to HIV persistence, particularly in the brain and lymph nodes, which can lead to complications such as AIDS-related dementia. Recent research has provided valuable insights into the role of chemokine receptors like CCR5 and CXCR4 in HIV infection, as well as the CCR5 delta32 mutation, which has helped to enhance our understanding of HIV resistance and progression. The virus's rapid mutation and immune evasion mechanisms continue to pose significant challenges in developing vaccines or achieving a cure. Additionally, the COVID-19 pandemic has disrupted HIV care, delaying testing, and treatment initiation, and complicating ART adherence, particularly for

vulnerable populations. However, the integration of HIV and COVID-19 responses, along with innovations in telehealth and digital interventions, offers opportunities for new healthcare models.

**Keywords:** HIV-1, Immune evasion Macrophages, Antiretroviral therapy (ART), COVID-19 pandemic, Disease progression Chemokine receptors

**Introduction:**

Human Immunodeficiency Virus (HIV) remains one of the most significant global public health challenges, continuing to affect millions of lives worldwide since its emergence in the 1980s. As of recent estimates, approximately 38.6 million people living with HIV-1 globally, and over 25 million people have died due to HIV-related illnesses (Haacker, 2024). The epidemic's dynamic nature, characterized by shifting transmission patterns, evolving geographic distributions, and increasing viral diversity, poses complex challenges to controlling and ultimately eradicating the virus. In this context, it is crucial to reflect on the current state of HIV research and emerging therapeutic approaches to understand where we stand and what the future may hold.

The prevalence and incidence of HIV vary significantly across different regions, with sub-Saharan Africa remaining the epicenter of the pandemic, though other regions, including parts of Asia, Eastern Europe, and Latin America, are also facing substantial burdens (Kaur & Vaccari, 2024). Vulnerable populations, such as men who have sex

with men, transgender individuals, sex workers, people who inject drugs, and young people, continue to be disproportionately affected (Rogers *et al.*, 2021). These groups experience heightened risks due to factors like stigma, discrimination, and limited access to healthcare services. In these regions, efforts to reduce transmission, such as promoting safer sex practices, the implementation of pre-exposure prophylaxis (PrEP), harm reduction programs, and the widespread availability of antiretroviral therapy (ART), have significantly improved health outcomes (Obeagu & Obeagu, 2024). However, emerging issues such as drug-resistant HIV strains, coinfection with other diseases, and access to care remain critical challenges (Singh *et al.*, 2020).

The predominant mode of HIV transmission remains heterosexual contact, accounting for around 85% of global infections, particularly in high-burden regions like Southern Africa (Bekker, *et al.*, 2023). This region continues to experience the highest rates of new infections, though other parts of the world, especially Eastern Europe and Asia, are increasingly affected by the spread of HIV through injecting drug use (Jolley *et al.*, 2012). Additionally, the burden of HIV infection among women has increased, with women now accounting for over 70% of those living with HIV in sub-Saharan Africa (Ramjee & Daniels, 2013). This shift highlights the significant implications for mother-to-child transmission and the heightened vulnerability of young women, particularly those under 25 years of age, due to socioeconomic factors and patterns of sexual behavior (Toska, *et al.*, 2020).

Another critical aspect of the HIV epidemic is the virus's genetic diversity. HIV-1 has evolved into multiple subtypes, with subtype C being the most prevalent globally (Hemelaar, 2013). The existence of circulating recombinant forms, which combine genetic material from different subtypes, further complicates the efforts to develop a comprehensive vaccine or therapeutic intervention (Tse *et al.*, 2020). This ongoing evolution poses a major challenge for researchers, as the virus adapts rapidly, evading both the immune system and antiviral therapies, thus making long-term control difficult (Lucas *et al.*, 2021).

The HIV pandemic's complexity is also reflected in its disease progression. After primary infection, individuals may remain asymptomatic for several years, while the virus actively replicates and progressively weakens the immune system, leading to the eventual development of acquired immunodeficiency syndrome (AIDS). The emergence of X4 HIV strains, typically associated with advanced disease stages, alongside the persistence of R5 strains, highlights the intricacies of HIV's interaction with the immune system (Nazziwa, 2022). Despite the progress made with ART, which has transformed HIV from a fatal disease to a manageable condition, the goal of complete eradication remains elusive. The complexities of HIV's pathogenesis and its capacity for rapid mutation necessitate novel therapeutic strategies aimed not only at controlling the infection but also at finding a cure.

The continuous evolution of HIV and the diverse subtypes present a moving target for researchers aiming to develop effective vaccines and therapies. Emerging therapies focus on multiple aspects of HIV's lifecycle, from inhibiting viral entry to targeting reservoirs where the virus persists despite treatment (Sengupta & Siliciano, 2018). The development of gene-editing technologies and the exploration of "shock and kill" strategies that target latent viral reservoirs offer hope for the future (Borrajó, 2025). However, overcoming the virus's capacity for immune evasion and the challenges posed by co-infections and drug resistance requires further innovation in research and treatment paradigms. This paper explores the latest developments in HIV research, with a particular focus on emerging therapies and novel approaches aimed at finding a cure. As our understanding of HIV-1's complex mechanisms deepens, and as new treatment strategies emerge, there is hope that transformative breakthroughs will eventually lead to the eradication of the virus. Global initiatives, combined with ongoing research and a sustained commitment to universal access to prevention, care, and treatment, are critical in the fight against HIV. Achieving the goal of ending the HIV epidemic by 2030 is within reach, but this will require collaborative efforts from governments, international organizations, civil

society, and the scientific community. By leveraging knowledge and advances in HIV research, we can move closer to a future where HIV no longer represents a threat to global health and well-being.

### **Material and methods**

This systematic review gathered insights from recent research on HIV-1 immune evasion, disease progression, and emerging therapies by conducting a comprehensive search across multiple reputable scientific databases such as PubMed, Scopus, and Web of Science, spanning from 2005 to December 2025. The inclusion criteria were peer-reviewed studies focused on HIV-1's immune evasion, macrophage infection, chemokine receptor usage, and therapeutic strategies, while studies on HIV-2 or SIV and non-peer-reviewed sources were excluded. Data was extracted on various variables, including HIV strain, immune evasion mechanisms, macrophage tropism, disease progression, and therapeutic interventions.

The data synthesis categorized studies into five main themes: immune evasion mechanisms (viral evolution and immune activation), macrophage tropism and HIV reservoirs, HIV disease progression, emerging therapies (e.g., ART and gene-editing), and the impact of co-infections, including tuberculosis and COVID-19. A narrative synthesis was employed due to the heterogeneous nature of the studies, identifying emerging trends, inconsistencies, and gaps in the research. The quality of studies was assessed using the Cochrane Risk of Bias Tool, Newcastle-Ottawa Scale, CASP checklist, and GRADE approach, rating studies on methodological rigor and relevance.

This review adhered to ethical guidelines using secondary data from published literature, with no direct patient data collection. While limitations included language restrictions, the variability of study designs, and the use of animal models, the review aimed to provide a comprehensive and accurate overview of HIV-1's immune evasion mechanisms and the progress in therapeutic strategies. The findings contribute to understanding how HIV-1 escapes immune surveillance, its progression, and the promising new treatments on the horizon.

### **Mechanism of HIV Infection**

HIV infection involves a series of complex steps that specifically target immune cells, particularly CD4+ T lymphocytes and macrophages. The virus begins by attaching to the CD4 receptors on the surface of these cells using its envelope glycoprotein, gp120 (Kwong *et al.*, 1998). Subsequently, it binds to co-receptors, either CCR5 or CXCR4, which allows the virus to enter the target cell (Dumas *et al.*, 2014). The fusion of HIV with the host cell membrane permits the virus to enter the cell's cytoplasm.

Once inside the host cell, the viral RNA is reverse-transcribed into double-stranded DNA by the viral enzyme reverse transcriptase (Liu *et al.*, 2008). This newly formed viral DNA integrates into the host cell's DNA with the help of the enzyme integrase, becoming a permanent part of the host cell's genetic material. Under specific conditions, the provirus becomes active and directs the synthesis of viral RNA and proteins.

Afterward, the viral RNA and proteins assemble at the cell surface, forming new viral particles that bud off from the host cell, acquiring their outer envelope from the host cell's membrane. During maturation, the viral proteins are cleaved into their functional forms by the viral enzyme protease, rendering the virus infectious.

These newly produced viral particles can then infect other CD4 cells and immune cells, perpetuating the cycle of infection and leading to a gradual decline in the immune system's function (Perelson, 1989). Understanding these intricate mechanisms has been vital in developing antiretroviral therapies that target different stages of the HIV life cycle, aiding in controlling viral replication and improving the quality of life for people living with HIV.

### **HIV-1 Immune Evasion and Disease Progression**

HIV-1's global spread highlights its ability to evade and counteract various components of the immune system. Despite its small genome and limited number of genes, HIV-1 effectively manipulates cellular pathways and remains undetected by the immune response (Armani-Tourret *et al.*, 2024). The majority of

pathogenesis understanding comes from studies on subtype B viruses and non-human primate models (Pandrea *et al.*, 2015).

HIV-1's life cycle is intricate, and its course depends on factors like the type of target cell and its activation. The virus enters host cells through interactions between the envelope glycoprotein (gp120) and the CD4<sup>+</sup> receptor, followed by co-receptor interactions (CCR5 or CXCR4) that lead to viral fusion (Yandrapally *et al.*, 2021). The viral genome is then reverse-transcribed into DNA, with the viral integrase enzyme facilitating its integration into the host's chromosomal DNA (Lewinski *et al.*, 2005). This results in the transformation of the host cell into a virus-producing factory. Viral replication involves both host-driven and virus-driven transcription, and viral proteins assemble near the cell membrane, ultimately resulting in the production of mature virions (Kalamvoki, 2025).

The virus utilizes the cell's vesicular sorting machinery for egress, incorporating host components that may affect its phenotype and immune responses. In early infection, after HIV-1 breaches the mucosal barrier, a window of opportunity exists where the host's defenses might limit viral expansion (Keele & Estes, 2011). Most new infections are CCR5-tropic, with CXCR4-tropic variants emerging in advanced stages of infection, associated with increased disease progression (Bader *et al.*, 2017)

Research in non-human primate models, particularly simian immunodeficiency virus (SIV) in rhesus macaques, suggests that vaginal transmission initially infects a small number of CD4<sup>+</sup> T cells, macrophages, and dendritic cells in the lamina propria (Hadzic, 2012). The virus amplifies in regional lymph organs, and after entering the bloodstream, it spreads to the gastrointestinal tract, spleen, and bone marrow, infecting susceptible cells (Brisse & Hickman, 2025). The peak of viral replication is accompanied by clinical symptoms during primary infection. As the infection becomes chronic, viral load decreases, partly due to CD8<sup>+</sup> cytotoxic T lymphocyte responses, though a diverse viral population evolves, potentially resistant to immune responses or treatment (McLane *et al.*, 2019).

A distinctive feature of HIV-1 infection is the depletion of activated and memory CD4<sup>+</sup> T cells, particularly in the gut-associated lymphoid tissues (GALT), which persist with antiretroviral therapy (Moretti *et al.*, 2023). This immune depletion, driven by general immune activation, contributes to disease progression, with AIDS being the final stage (Sodora & Silvestri, 2008). Though symptoms may not be apparent in early or chronic stages, viral replication remains dynamic, and the virus turnover is rapid, with millions of virions produced daily. Host immune activation is a key predictor of disease progression.

Natural resistance to HIV-1 infection is rare but has been observed in individuals with specific genetic factors, such as HLA haplotypes, mutations in CCR5 and CCR2, and variations in CCL3L1 gene copy number (Kumar *et al.*, 2006). Some individuals, including long-term non-progressors and persistently seronegative individuals, exhibit immune responses that can limit viral replication or confer resistance (Poropatich & Sullivan 2011). The role of cytotoxic T lymphocytes and helper T cells in these individuals highlights the complexity of host immunity in HIV-1 control.

HIV-1 also faces intrinsic host defense factors, such as APOBEC3G/3F and TRIM5 $\alpha$ , which provide an antiviral response by limiting viral replication (Gers-Huber, 2015). However, HIV-1 has evolved mechanisms to evade these defenses, particularly by expressing the Vif protein, which degrades APOBEC3G/3F (Ran *et al.*, 2016). Despite these challenges, research continues to explore how these intrinsic factors can be leveraged to develop novel therapeutic strategies, including vaccine and antiviral treatments, to combat HIV-1 (Weerarathna *et al.*, 2024).

### **The Impact of The COVID-19 Pandemic on HIV**

The COVID-19 pandemic has had a profound impact on the HIV response, with widespread disruptions in healthcare services, leading to delayed testing, diagnosis, and treatment initiation (Rick *et al.*, 2022). Lockdown measures and fear of contracting COVID-19 deterred people from seeking HIV testing, raising concerns about undiagnosed cases. Additionally, HIV prevention efforts faced challenges due to social distancing

measures, impacting condom distribution and harm reduction initiatives among vulnerable populations.

Individuals living with HIV encountered obstacles in adhering to their treatment regimens, as access to medications became limited during the pandemic. Vulnerable populations, including marginalized communities and those with limited healthcare access, faced heightened risks of both HIV and COVID-19 due to existing health disparities. The pandemic also took a toll on the mental health of individuals living with HIV, leading to increased feelings of social isolation, anxiety, and depression (Roy *et al.*, 2021).

Healthcare providers adapted by using telehealth and digital interventions to provide HIV care remotely, ensuring continuity of services. Integration of HIV and COVID-19 responses presented opportunities for optimizing healthcare systems and resource utilization. However, the pandemic also posed challenges for HIV research and funding, potentially impacting progress in prevention and treatment efforts (Sanchez *et al.*, 2020).

Addressing the impact of the COVID-19 pandemic on HIV requires targeted strategies, such as innovative testing approaches, continuous medication access, scaled-up telehealth services, and addressing mental health needs. It necessitates sustained efforts to ensure equitable healthcare access, continued funding for HIV programs, and a focus on the well-being of individuals living with HIV. Despite the challenges, the pandemic has underscored the importance of resilience, innovation, and collaboration in maintaining and advancing HIV services during extraordinary circumstances.

### **Role of Inflammation and Immune Activation in HIV Infection**

Inflammation and immune activation play a significant role in the susceptibility of mononuclear phagocytes and other cells to HIV infection, particularly in the advanced stages of the disease. Various environmental factors, including cytokines and chemokines, influence disease progression and HIV pathogenesis (Cribbs *et al.*, 2020). Viral replication can be

stimulated by factors such as vaccination, cytokine induction, beta chemokines, endotoxins, and opportunistic infections from different pathogens (Manna *et al.*, 2020).

Cytokines, particularly Th1 and Th2 cytokines, are crucial in HIV infection and the development of AIDS (Gorenec *et al.*, 2016). In HIV-infected individuals, the normal Th1 response, typically involved in viral defense, is shifted towards a Th2 response, which may enhance HIV replication. Several cytokines, including TNF-alpha, IL-1, IL-2, IL-3, IL-12, MCSF, GMCSF, and IL-6, have been shown to promote HIV replication and play a role in AIDS-related malignancies (Tayal *et al.*, 2008). In contrast, some cytokines like IFN-alpha and -beta inhibit HIV replication (Muema *et al.*, 2020). Cytokines such as TGF-beta, IL-4, IL-10, IL-13, and IFN-gamma have dual effects on HIV replication, either stimulating or inhibiting viral replication depending on the cell type and experimental conditions (Alfano & Poli, 2012). For example, IL-16 inhibits HIV replication, a finding consistent across several studies (Kornfeld, & Cruikshank, 2001). In another research, IL-16 inhibited both R5 and X4 strains of HIV-1 replication in macrophages, independently of its effect on the chemokine receptors CCR5, CXCR4, and CD4 (Herbein & Varin, 2010)

Chemokine receptors, chemokines, and their interactions with HIV are critical in the progression of HIV disease. CCR5 ligands (such as RANTES, MIP-1alpha, and MIP-1beta) and CXC chemokine receptor 4 (SDF1) have been shown to block HIV entry into CD4+ T cells, PBMCs, and monocytic cells (Schools, 2004). Due to their inhibitory effects on HIV entry, increased production of these chemokines is suggested as a protective immune response against HIV infection and disease progression. Research has shown that beta-chemokines when exposed to monocytes and macrophages, can have varying effects on HIV replication depending on the timing of exposure (Kedzierska *et al.*, 2003). These effects are particularly important in understanding the resistance of primary SI strains to beta-chemokines and their sensitivity to SDF1. Furthermore, beta-chemokines can promote T-

tropic strains in CD4 T-cells, highlighting the complexity of the chemokine-mediated response in HIV infection.

Finally, dysregulation of cytokine and chemokine expression has been observed in HIV, underlining the importance of these molecules in the virus's ability to manipulate the immune system and influence disease progression (Emilie & Galanaud, 2001).

### **Advancements in HIV Treatment**

Advancements in HIV treatment have transformed the management of the virus, turning it into a manageable chronic condition. The introduction of antiretroviral therapy (ART) in the mid-1990s marked a pivotal moment in HIV treatment. ART, a combination of different antiretroviral drugs targeting various stages of the HIV life cycle, effectively controls viral replication, reduces virus levels in the body, and slows the progression of HIV to AIDS (Deeks *et al.*, 2015). Highly Active Antiretroviral Therapy (HAART) takes this approach further by combining multiple antiretroviral drugs from different classes, preventing drug resistance and improving treatment efficacy.

Fixed-dose combination (FDC) therapy has simplified treatment regimens by combining multiple antiretroviral drugs into a single pill (Desai *et al.*, 2013). This innovation has reduced pill burden and improved medication adherence, leading to better treatment outcomes. International organizations like the WHO and UNAIDS have developed treatment guidelines promoting early initiation of ART for all people living with HIV, irrespective of their CD4 cell count, through the "Test and Treat" approach (Nash *et al.*, 2018). This strategy ensures timely access to treatment, improving health outcomes, and reducing transmission rates.

Advancements also extend to prevention efforts. Long-acting antiretroviral therapy options, such as injectables or implants, are being researched to reduce the frequency of daily dosing, enhancing treatment adherence (Cobb *et al.*, 2020). Prevention of Mother-to-Child Transmission (PMTCT) interventions, which involve administering antiretroviral drugs to

pregnant women and infants, significantly reduce transmission risks (World Health Organization, 2010). Moreover, the concept of Treatment as Prevention (TasP) has been established, showing that individuals with undetectable viral loads from effective ART are highly unlikely to transmit HIV to their sexual partners (Bor *et al.*, 2021).

### **Impact of R5 and X4 HIV-1 Variants on Disease Progression and Evolution**

HIV-1 exists as a highly heterogeneous virus, with distinct strains differing in their biological, serological, and molecular characteristics, which significantly impact the virus's behavior during infection. R5 M-tropic strains are the predominant variants in the early stages of infection and continue to persist through the progression of the disease (Zhou *et al.*, 2023). These strains primarily infect monocytes and macrophages, with their persistence contributing to ongoing viral replication. Research has shown that R5 strains derived from the advanced stages of infection are more infectious and exhibit enhanced cytopathic effects compared to those from earlier stages (Locher *et al.*, 2005). Additionally, R5 strains are often limited in replication in undifferentiated monocytes, but over time, they evolve to become biologically fit and able to infect more efficiently in later stages of disease, particularly in the presence of specific immune system pressures and viral evolution.

The emergence of X4-tropic strains occurs later in infection, with approximately 40% of individuals developing these variants after years of chronic HIV-1 infection (Zhou *et al.*, 2023). X4 strains are associated with accelerated disease progression, largely due to their enhanced ability to infect CD4+ T cells, leading to greater immune depletion. These strains use the CXCR4 receptor for entry, which is typically expressed on a broader range of precursor cells in the late stages of infection (Zirafi *et al.*, 2015). This broadened target cell range allows X4 variants to maintain high levels of replication even as the CD4+ T cell population becomes severely depleted. Despite the substantial loss of CD4+ T cells, X4 strains can thrive in other cell types, such as macrophages, which remain susceptible to infection by these variants

(Wickham, 2019). This ability to infect alternative target cells complicates the understanding of their role in disease progression and the mechanisms by which X4 strains persist and replicate.

The precise mechanisms behind the emergence and persistence of X4 strains remain unclear, despite their recognized role in disease progression. It is postulated that X4 variants emerge from a relatively homogeneous R5 viral population through viral evolution, but the factors that drive this transition are still under investigation (Abisi, 2023). Host factors, such as immune system pressure, cell maturation, and sensitivity to chemokines, likely play a role in this shift (Bonecchi *et al.*, 2009). The evolution of X4 strains is particularly concerning as it represents a shift toward more aggressive viral replication and contributes to the rapid progression toward AIDS. Understanding the dynamics between R5 and X4 variants, including the factors that drive their emergence and persistence, is crucial in the search for effective therapies and ultimately a cure for HIV-1.

### **Macrophage Tropism, Coreceptor Usage, and HIV-1 Disease Progression**

Macrophages play a crucial role as reservoirs and facilitators of HIV-1 infection in various tissues, including the brain, lungs, lymph nodes, skin, and bone marrow. Infected macrophages serve as sources of viral replication, contributing to the persistence of HIV-1 even during highly active antiretroviral therapy (HAART) (Kruize & Kootstra, 2019). Notably, HIV-infected macrophages in the brain and lymph nodes produce large quantities of viral particles, which can be critical in the development of AIDS-related complications such as dementia. The persistence of infection in macrophages is a significant factor in the regulation and progression of the disease, with their secretory products playing a role in AIDS dementia complex and immune dysregulation (Borrajó *et al.*, 2021). The susceptibility of macrophages to HIV infection is influenced by factors such as chemokine receptor expression, including CCR5, CXCR4, and CCR3, which vary between neonatal and adult cells, potentially affecting vertical transmission and disease dynamics (Nazziwa, 2022).

The progression from acute HIV-1 infection to AIDS is characterized by immune system dysregulation and a shift in HIV dynamics, including an increase in infected macrophages in addition to CD4<sup>+</sup> T cells (Hendricks *et al.*, 2021). While HAART can minimize opportunistic infections (OIs) and induce immune reconstitution, it does not fully eradicate the virus, especially in macrophages, which continue to harbor persistent infection (Kruize *et al.*, 2019). The activation of viral coreceptors, such as CCR5 and CXCR4, as well as the production of cytokines like TNF-alpha, can further stimulate viral replication in infected macrophages (Pasquereau *et al.*, 2017). Despite antiviral mechanisms like apoptosis targeting infected T cells, macrophages remain a crucial sanctuary for the virus, contributing to the ongoing challenge of HIV treatment. Understanding the interplay between macrophage susceptibility, coreceptor usage, and immune activation is essential to addressing HIV persistence and developing effective therapies.

CCR5 polymorphism is another important factor influencing HIV susceptibility and disease progression (Lama & Planelles, 2007). The CCR5 delta32 mutation, which leads to the absence of functional CCR5 receptors on CD4<sup>+</sup> T cells and macrophages, confers partial resistance to HIV-1 infection (Barmania & Pepper, 2013). Individuals homozygous for this mutation (CCR5delta32/delta32) are largely resistant to R5 HIV-1 strains, while heterozygous individuals tend to progress more slowly to AIDS (Mohamed *et al.*, 2022). Interestingly, viruses isolated from these individuals tend to be T-tropic and utilize CXCR4 as their coreceptor, replicating well in T cells but not in macrophages (Duri, 2012). This shift in coreceptor usage underlines the complexity of HIV-1 tropism, where coreceptor preferences influence viral entry and replication in different cell types, impacting disease progression. The discovery of chemokine receptors as coreceptors has greatly enhanced our understanding of HIV entry and cellular tropism, offering new insights into potential therapeutic strategies targeting these pathways (Panos *et al.*, 2015).

### Challenges in HIV Treatment

Despite significant progress, challenges persist. Lifelong adherence to medication, potential side effects, ensuring access to treatment in resource-limited areas, and addressing disparities in HIV care among different populations remain pressing concerns. However, continuous research and efforts aim to improve HIV treatment further, with the ultimate aspiration of finding a cure for HIV. As advancements continue, the global effort to combat the HIV epidemic remains steadfast in providing comprehensive and effective care for individuals living with HIV.

### Prevention Efforts Against HIV

Prevention efforts against HIV encompass a range of strategies and interventions to combat the spread of the virus and raise awareness. Safer sex education emphasizes consistent and correct condom use and the risks of unprotected sex (Fisher, *et al.*, 199). Voluntary counseling and testing (VCT) encourage HIV testing and counseling to facilitate early detection and access to treatment. Pre-exposure prophylaxis (PrEP) is an effective preventive approach for individuals at high risk, involving regular use of antiretroviral drugs to reduce infection risk (Alistar *et al.*, 2014).

### Emerging Therapies for HIV

Ongoing research is focused on exploring emerging therapies for HIV to enhance treatment options and address challenges in HIV management. Long-acting antiretroviral drugs, administered through injections or implants, aim to simplify treatment regimens and improve adherence (Cobb *et al.*, 2020). Researchers are also investigating novel drug classes and optimizing existing ones, such as integrase inhibitors and non-nucleoside reverse transcriptase inhibitors, to target HIV more effectively (Himmel & Arnold, 2020).

Broadly, neutralizing antibodies (bNAbs) are promising for both treatment and prevention, as they can neutralize various HIV strains (Awan *et al.*, 2022). Gene therapies, like CRISPR-Cas9, are being explored as potential cures to modify immune cells and combat latent HIV reservoirs in the body (Deng *et al.*, 2018). Immune-based

therapies, including immune checkpoint inhibitors and therapeutic vaccines, seek to enhance the body's immune response to control viral replication (Bailon *et al.*, 2020).

Latency-reversing agents (LRAs) are being studied to activate dormant HIV in reservoir cells, making them vulnerable to the immune system and antiretroviral drugs, potentially contributing to an HIV cure (Ait-Ammar *et al.*, 2020). Microbicides, such as gels or creams, are being researched to prevent HIV transmission during sexual activity (Garg *et al.*, 2010).

Multi-targeted therapy combinations, addressing different stages of the HIV life cycle, are being investigated to improve treatment efficacy and reduce drug resistance risks (Ananworanich *et al.*, 2012). As the field of HIV research is dynamic, ongoing efforts in clinical trials are crucial to assess the safety and effectiveness of these emerging therapies. Collaborative endeavors among researchers, healthcare professionals, and scientific communities are vital to advancing these therapies and working toward the goal of ending the HIV epidemic. For the latest information on HIV research, it is recommended to refer to current scientific literature and reputable research organizations.

Prevention of mother-to-child transmission (PMTCT) involves administering antiretroviral drugs to pregnant women and infants to reduce transmission risks during pregnancy, childbirth, and breastfeeding (Ton & Frenkel, 2013). Harm reduction programs target people who inject drugs, offering clean needles, syringe exchange, and substance abuse treatment to reduce HIV transmission. Behavior change interventions through educational campaigns and community outreach address misconceptions, and stigma, and promote positive behaviors related to sexual activity and drug use.

HIV education and awareness campaigns reach communities, schools, and workplaces, dispelling myths and encouraging regular HIV testing. Community-based interventions empower individuals through peer education and support groups tailored to different populations'

needs. Empowering women and girls through gender equality, education, and reproductive health services reduces their vulnerability to HIV. Finally, treatment as prevention (TasP) promotes early HIV testing and treatment to reduce transmission risks when viral loads are undetectable. By combining these comprehensive prevention efforts, the global burden of HIV can be reduced, leading to progress in combating the epidemic and moving toward ending HIV.

### **Global Efforts to Combat HIV**

Global efforts to combat HIV have been marked by the collaboration and involvement of various organizations, governments, civil society groups, and individuals worldwide. The Joint United Nations Programme on HIV/AIDS (UNAIDS) takes a leading role in coordinating global HIV responses, uniting ten UN agencies to provide leadership, advocate for effective policies, mobilize resources, and support countries in their efforts to address HIV (UNAIDS, 1995). UNAIDS set ambitious 90-90-90 targets to ensure that 90% of people living with HIV know their status, 90% of those diagnosed receive antiretroviral treatment, and 90% of those on treatment achieve viral suppression by 2020 (Bain *et al.*, 2017).

Financial support for HIV initiatives is crucial, and The Global Fund to Fight AIDS, Tuberculosis, and Malaria plays a significant role in this aspect. This partnership between governments, civil society, the private sector, and affected communities provides financial resources to support HIV prevention, treatment, and care programs in countries with high disease burdens. PEPFAR, initiated by the United States government in 2003, is a bilateral program offering financial and technical assistance to combat HIV in over 50 countries, with a focus on sub-Saharan Africa (El-Sadr *et al.*, 2012).

International collaboration is a key aspect of global HIV efforts. The World Health Organization (WHO) sets global guidelines on HIV treatment and prevention, supporting countries in implementing evidence-based interventions and promoting access to quality healthcare services. Research organizations,

such as the International AIDS Vaccine Initiative (IAVI), are driving efforts to develop an effective HIV vaccine (WHO, 2016).

Additionally, global prevention campaigns, like World AIDS Day, raise awareness, combat stigma, and advocate for increased funding and support for HIV prevention and treatment programs. The Global HIV Prevention Coalition brings together governments, civil society, and international organizations to accelerate HIV prevention efforts, especially among key populations. Adopting the Treat All approach, many countries initiate antiretroviral treatment for all people living with HIV, irrespective of CD4 cell count, to reduce transmission and improve health outcomes.

By leveraging these collaborative global efforts, significant progress has been made in reducing new HIV infections, expanding access to treatment, and improving the quality of life for people living with HIV. However, continued commitment, funding, and cooperation are essential to sustain these achievements and work towards ending the HIV epidemic by 2030.

### **Awareness and Education on HIV**

Awareness and education on HIV are vital in the global fight against the virus. Governments, NGOs, and international organizations run public awareness campaigns through various media channels to inform the general population about HIV, its transmission, prevention, and treatment (World Health Organization, 2022). School-based education empowers students to make informed decisions about their sexual health, while community outreach and workshops address cultural norms and engage communities in discussions about HIV-related issues (Obeagu *et al.*, 2024). These efforts aim to reduce stigma and discrimination associated with HIV, promote HIV testing and counseling services, and provide tailored prevention and treatment options for key populations at higher risk.

Capacity building for healthcare providers ensures accurate information, counseling, and quality care for individuals living with HIV (Dawson-Rose *et al.*, 2016). World AIDS Day is an annual awareness event that brings people together to

show support for those affected by HIV and raise awareness about prevention and treatment (Irwin *et al.*, 2003,). Peer-led education programs foster trust and behavior change, and online platforms provide access to information, testing locations, and support networks.

By promoting widespread awareness and education on HIV, we can create a more compassionate and informed society, reduce new infections, and improve the overall well-being of people living with HIV. These efforts play a crucial role in combatting stigma, dispelling misconceptions, and encouraging early testing and treatment for better health outcomes.

### **Vulnerable Populations of HIV Infection**

Vulnerable populations are groups facing higher risk of HIV infection and barriers to accessing essential HIV prevention, testing, treatment, and care services. These include men who have sex with men (MSM), transgender individuals, sex workers, people who inject drugs (PWID), incarcerated individuals, adolescents and youth, migrant populations, people experiencing homelessness, Indigenous communities, and those with limited healthcare access (Onwuliri & Jolayemi, 2006). Each group faces distinct challenges that contribute to their vulnerability to HIV.

Addressing HIV among vulnerable populations requires a comprehensive and tailored approach. Efforts should encompass community engagement, advocacy for equal rights and access to healthcare, and targeted interventions designed to meet the unique needs of each group. Reducing stigma, discrimination, and legal barriers is crucial in promoting access to HIV prevention and healthcare services (Obeagu, 2024). Moreover, providing culturally competent healthcare and comprehensive sexual education is essential to empowering these populations to protect themselves from HIV and improve their overall health and well-being. Collaborative global efforts should focus on mitigating the impact of HIV on vulnerable populations and working towards a more inclusive and equitable HIV response (WHO,2009).

### **Novel Approaches to HIV Treatment**

HIV research remains an active field with a focus on various areas to combat the virus. Research on

HIV vaccines is ongoing, exploring different candidates and novel approaches to stimulate an effective immune response. Long-acting antiretroviral therapies (ART) are being studied to improve treatment adherence, and efforts to find an HIV cure continue, with investigations into gene therapies, latency-reversing agents, and immune-based approaches (Kerrigan *et al.*, 2020).

Prevention technologies are being developed, including multipurpose prevention technologies, and tailored interventions for specific populations such as women and key populations are under exploration. Treatment strategies are being refined, considering the optimal timing of ART initiation and personalized regimens based on viral resistance patterns. The impact of the COVID-19 pandemic on HIV services is being examined to ensure the continuity of care (Jiang *et al.*, 2020).

HIV research also encompasses social and behavioral studies to understand factors influencing HIV transmission and engagement with healthcare services. Implementation science is crucial in identifying effective strategies for delivering HIV prevention and treatment interventions in real-world settings. Additionally, studies on co-infections and comorbidities are exploring interactions with diseases like tuberculosis, hepatitis C, and non-communicable diseases (Righetto *et al.*, 2014).

Research on pre-exposure prophylaxis (PrEP) seeks to optimize drug formulations, dosing regimens, and implementation strategies to enhance PrEP uptake and effectiveness in preventing HIV transmission (Sidebottom *et al.*, 2018) Collaboration between scientists, healthcare providers, communities, and policymakers remains vital in translating research findings into impactful interventions. Up-to-date information can be found in the latest scientific literature, as the field continues to evolve and progress in the fight against HIV.

### **Cutting-Edge Discoveries in HIV Research**

One of the most notable cutting-edge discoveries in HIV research was the identification of the HIV-1 mosaic vaccine candidate (Haynes *et al.*, 2014). This innovative vaccine aims to address the genetic diversity of the virus, which poses

challenges to developing a single vaccine capable of protecting against all HIV strains. Mosaic vaccines are designed to incorporate components from different HIV strains, creating a synthetic representation of global viral diversity. In a preclinical study involving non-human primates, the mosaic vaccine demonstrated promising results by eliciting strong and broad immune responses, indicating its potential effectiveness against a wide range of HIV variants (Safrit *et al.*, 2016).

Despite these encouraging findings, it is essential to recognize that the mosaic vaccine candidate was still in the early stages of development. Further research and clinical trials in humans were necessary to determine its safety and efficacy in preventing HIV infection. This discovery represents a significant step forward in the quest for an effective HIV vaccine, but ongoing research and collaboration across the scientific community remain crucial to advancing HIV prevention strategies.

### **Targeted Therapies of HIV Using Medicinal Plants**

Targeted therapies for HIV using medicinal plants have gained interest in complementary and alternative medicine. Certain medicinal plants, such as aloe vera, echinacea, curcumin (from turmeric), and ginkgo biloba, have shown potential antiviral properties against HIV in laboratory studies (Katsa & Yakubu, 2022). Aloe vera gel and its compounds have demonstrated inhibition of HIV replication and reduction in viral load in vitro (Dong *et al.*, 2022). Echinacea's compounds also exhibit antiviral activity, possibly inhibiting viral replication (Mandal *et al.*, 2020). Curcumin has been found to suppress HIV replication and reduce viral production in infected cells, while certain components in ginkgo biloba may inhibit HIV replication and reduce viral infectivity (Prasad & Tyagi, 2015). However, these findings are preliminary, and further research, including clinical trials, is needed to validate their efficacy and understand their mechanisms of action fully.

Despite the potential shown in these medicinal plants, it is essential to emphasize that they should not replace conventional antiretroviral therapy

(ART) for managing HIV effectively. ART remains the standard of care for HIV treatment, improving patient outcomes and suppressing viral replication (Foka *et al.*, 2023). Medicinal plant-based therapies should be considered as complementary approaches and should be discussed with qualified healthcare professionals to ensure safety and appropriate usage.

### **Most Common Opportunistic Infection in Individuals Living With HIV**

The most common opportunistic infection in individuals living with HIV is *Pneumocystis jirovecii* pneumonia (PJP), caused by the fungus *Pneumocystis jirovecii* (Avino *et al.*, 2016). Before effective antiretroviral therapy, PJP was a leading cause of morbidity and mortality in people with advanced HIV, particularly those with low CD4 cell counts (Hull *et al.*, 2008). The weakened immune system in HIV-positive individuals allows the fungus to multiply in the lungs, leading to pneumonia. However, with the widespread use of antiretroviral therapy, the incidence of PJP has significantly decreased in those with access to effective treatment, as it helps restore the immune system's function.

In addition to PJP, other opportunistic infections can affect people with advanced HIV and compromised immune systems. These infections may be caused by bacteria, viruses, fungi, and parasites, including tuberculosis, candidiasis, cytomegalovirus (CMV) infections, and toxoplasmosis, among others (Huang & Crothers, 2009). Preventing opportunistic infections in people with HIV involves regular medical care, adherence to antiretroviral therapy, and timely use of prophylactic medications, particularly when CD4 cell counts are low. Close monitoring of immune status and timely preventive measures and treatments are vital to reducing the risk of opportunistic infections.

Overall, advances in HIV treatment have significantly improved the prognosis of individuals living with HIV, allowing them to lead longer and healthier lives. Nevertheless, vigilance in managing opportunistic infections and ensuring continued access to comprehensive care and antiretroviral therapy remain crucial in optimizing health outcomes for people with HIV.

## Challenges of HIV

Challenges of HIV remain significant, with stigma and discrimination posing barriers to prevention, testing, and treatment efforts. Limited access to quality healthcare, especially for marginalized populations, hinders the management of HIV. Drug resistance is a concern, necessitating improved medication adherence and access to newer drugs (Brown *et al.*, 2016). Health disparities persist, with racial and ethnic minorities facing higher HIV rates and worse outcomes. Adolescents and young adults remain at risk due to limited education and prevention resources, while comorbidities among those living with HIV require specialized management (Dahourou *et al.*, 2017). Adequate funding and resources are crucial to sustaining the fight against HIV.

However, the prospects of HIV response show promise. Advances in treatment, especially with newer antiretroviral therapies, have improved the well-being of individuals living with HIV (Oguntibeju, 2012). Prevention strategies like PrEP and TasP have proven effective in reducing HIV transmission rates (Bernays *et al.*, 2021). Ongoing research in vaccine development offers hope for an effective preventive measure (Excler *et al.*, 2021). Combining multiple prevention methods can have a synergistic effect in reducing HIV incidence. Public awareness campaigns can promote increased testing and timely treatment (Kurth *et al.*, 2011). Supportive policies protecting the rights of those living with HIV and fostering access to healthcare enhance the overall response. Global collaborations and partnerships continue to drive progress in HIV research, prevention, and treatment efforts.

While challenges persist, the strides made in the global response to HIV underscore the importance of continued commitment, innovation, and collaboration to ultimately end the HIV epidemic.

## Conclusion.

HIV remains a significant global public health challenge, with varying prevalence across regions, disproportionately affecting vulnerable populations due to stigma and limited healthcare access. Despite progress in HIV prevention efforts

through safer sex practices, PrEP implementation, and harm reduction programs, challenges such as limited healthcare access and drug-resistant strains persist. Ongoing research on emerging therapies, including vaccines, long-acting ART, gene therapies, and immune-based approaches, offers promising potential for the future. Comprehensive awareness campaigns, global collaborative efforts, and tailored approaches for vulnerable populations are crucial in combatting stigma, encouraging testing, and promoting early treatment. The COVID-19 pandemic brought unique challenges to the HIV response, but adaptability through telehealth and digital interventions ensured continuity of care. Addressing the pandemic's impact on HIV requires targeted strategies, continuous medication access, and collaboration to advance HIV services. The journey towards an HIV cure continues, with sustained commitment, innovation, and collaboration aiming to ultimately end the HIV epidemic and empower individuals living with HIV to lead fulfilling lives with optimal health and well-being.

**Conflict of Interest:** The authors declare no conflicts of interest

## References

- Abisi, H. K. (2023). *HIV-1 Genetic Diversity in Nairobi Female Sex Workers* (Doctoral dissertation, University of Nairobi).
- Ait-Ammar, A., Kula, A., Darcis, G., Verdikt, R., De Wit, S., Gautier, V., ... & Van Lint, C. (2020). Current status of latency-reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. *Frontiers in Microbiology*; **10**: 3060.
- Alfano, M., & Poli, G. (2012). Cytokines and HIV Infection. In *Soluble Factors Mediating Innate Immune Responses to HIV Infection*. Bentham Science Publishers: 17-50.
- Alistar, S.S., Grant, P.M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. *BMC Medicine*; **12**(1): 1-11.
- Ananworanich, J., Schuetz, A., Vandergeeten, C., Sereti, I., De Souza, M., Rerknimitr, R., ... & RV254/SEARCH 010 Study Group.

- (2012). Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. *PloS One*; **7(3)**: e33948.
- Armani-Tourret, M., Bone, B., Tan, T. S., Sun, W., Bellefroid, M., Struyve, T., ... & Lichterfeld, M. (2024). Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. *Nature Reviews Microbiology*; **22(6)**: 328-344.
- Avino, L. J., Naylor, S. M., & Roecker, A. M. (2016). Pneumocystis jirovecii pneumonia in the non-HIV-infected population. *Annals of Pharmacotherapy*; **50(8)**: 673-679.
- Awan, S. F., Happe, M., Hofstetter, A. R., & Gama, L. (2022). Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. *Current Opinion in HIV and AIDS*; **17(4)**: 247-257.
- Bader, J., Däumer, M., Schöni-Affolter, F., Böni, J., Gorgievski-Hrisoho, M., Martinetti, G., ... & Swiss HIV Cohort Study. (2017). Therapeutic immune recovery and reduction of CXCR4-tropic HIV-1. *Clinical Infectious Diseases*; **64(3)**: 295-300.
- Bailon, L., Mothe, B., Berman, L., & Brander, C. (2020). Novel approaches towards a functional cure of HIV/AIDS. *Drugs*; **80(9)**: 859-868.
- Bain, L. E., Nkoke, C., & Noubiap, J. J. N. (2017). UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on "Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades". *BMJ Global Health*; **2(2)**: e000227.
- Barmania, F., & Pepper, M. S. (2013). CC chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. *Applied & Translational Genomics*; **2**: 3-16.
- Bekker, L. G., Beyrer, C., Modi, N., Lewin, S. R., Delany-Moretlwe, S., Taiwo, B., ... & Lazarus, J. V. (2023). HIV infection. *Nature Reviews Disease Primers*; **9(1)**: 42.
- Bernays, S., Bourne, A., Kippax, S., Aggleton, P., & Parker, R. (2021). *Remaking HIV prevention: The promise of TasP, U=U and PrEP*. Springer International Publishing: 1-18.
- Bonecchi, R., Galliera, E., Borroni, E. M., Corsi, M. M., Locati, M., & Mantovani, A. (2009). Chemokines and chemokine receptors: an overview. *Frontiers of Bioscience*; **14(1)**: 540-551.
- Bor, J., Fischer, C., Modi, M., Richman, B., Kinker, C., King, R., ... & Onoya, D. (2021). Changing knowledge and attitudes towards HIV treatment-as-prevention and undetectable= untransmittable: a systematic review. *AIDS and Behavior*; **25(12)**: 4209-4224.
- Borrajo, A. (2025). Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication. *Life*; **15(2)**: 276.
- Borrajo, A., Spuch, C., Penedo, M. A., Olivares, J. M., & Agís-Balboa, R. C. (2021). The important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis. *Annals of Medicine*; **53(1)**: 43-69.
- Brisse, M. E., & Hickman, H. D. (2025). Viral Infection and Dissemination Through the Lymphatic System. *Microorganisms*; **13(2)**: 443.
- Brown, M. T., Bussell, J., Dutta, S., Davis, K., Strong, S., & Mathew, S. (2016). Medication adherence: truth and consequences. *The American Journal of The Medical Sciences*; **351(4)**: 387-399.
- Cobb, D. A., Smith, N. A., Edagwa, B. J., & McMillan, J. M. (2020). Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. *Expert Opinion on Drug Delivery*; **17(9)**: 1227-1238.
- Cribbs, S. K., Crothers, K., & Morris, A. (2020). Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. *Physiological Reviews*; **100(2)**: 603-632.
- Dahourou, D. L., Gautier Lafaye, C., Teasdale, C. A., Renner, L., Yotebieng, M., Desmonde, S., ... &
- Leroy, V. (2017). The transition from pediatric to adult care of adolescents living with HIV in sub-Saharan Africa: challenges, youth friendly models, and outcomes. *Journal of the International AIDS Society*; **20**: 21528.

- Dawson-Rose, C., Cuca, Y. P., Webel, A. R., Báez, S. S. S., Holzemer, W. L., Rivero-Méndez, M., ... & Lindgren, T. (2016). Building trust and relationships between patients and providers: an essential complement to health literacy in HIV care. *Journal of the Association of Nurses in AIDS Care*; **27(5)**: 574-584.
- Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015). HIV infection. *Nature reviews Disease Primers*; **1(1)**: 1-22.
- Deng, Q., Chen, Z., Shi, L., & Lin, H. (2018). Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV 1 infection. *Reviews in Medical Virology*; **28(5)**: e1998.
- Desai, D., Wang, J., Wen, H., Li, X., & Timmins, P. (2013). Formulation design, challenges, and development considerations for fixed-dose combination (FDC) of oral solid dosage forms. *Pharmaceutical Development and Technology*; **18(6)**: 1265-1276.
- Dong, S., Yu, R., Wang, X., Chen, B., Si, F., Zhou, J., ... & Zhang, D. (2022). Bis-benzylisoquinoline alkaloids inhibit porcine epidemic diarrhea virus in vitro and in vivo. *Viruses*; **14(6)**: 1231.
- Dumas, F., Preira, P., & Salomé, L. (2014). The membrane organization of the virus and target cell plays a role in HIV entry. *Biochemistry*; **107**: 22-27.
- Duri, K. (2012). Coreceptor usage in HIV infection. In *Immunodeficiency. IntechOpen*: 235-258.
- El-Sadr, W. M., Holmes, C. B., Mugenyi, P., Thirumurthy, H., Ellerbrock, T., Ferris, R., ... & Whiteside, A. (2012). Scale-up of HIV treatment through PEPFAR: a historic public health achievement. *Journal of Acquired Immune Deficiency Syndromes (1999)*; **60(3)**: S96.
- Emilie, D., & Galanaud, P. (2001). Cytokines and chemokines in HIV infection: implications for therapy. *Cytokines and Cytokine Receptors*: 679-696.
- Excler, J. L., Saville, M., Berkley, S., & Kim, J. H. (2021). Vaccine development for emerging infectious diseases. *Nature Medicine*; **27(4)**: 591-600.
- Fisher, J. D., Fisher, W. A., Misovich, S. J., Kimble, D. L., & Malloy, T. E. (1996). Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. *Health Psychology*; **15(2)**: 114.
- Foka, F. E. T., & Mufhandu, H. T. (2023). Current ARTs, virologic failure, and implications for AIDS management: a systematic review. *Viruses*; **15(8)**: 1732.
- Garg, S., Goldman, D., Krumme, M., Rohan, L. C., Smoot, S., & Friend, D. R. (2010). Advances in development, scale-up, and manufacturing microbicide gels, films, and tablets. *Antiviral Research*; **88**: S19-S29.
- Gers-Huber, G. (2015). *Identification of cellular HIV restriction factors and host-HIV interactions* (Doctoral dissertation, University of Zurich).
- Gorenec, L., Lepej, S. Z., Grgic, I., Planinic, A., Bes, J. I., Vince, A., & Begovac, J. (2016). The comparison of Th1, Th2, Th9, Th17, and Th22 cytokine profiles in acute and chronic HIV-1 infection. *Microbial Pathogenesis*; **97**: 125-130.
- Haacker, M. (2024). 1. The Demographic Impact of HIV/AIDS. In *The Macroeconomics of HIV/AIDS*. International Monetary Fund.
- Hadzic, S. V. (2012). *Comparative studies of vaginal SIV transmission and effects on female reproductive tissues of Rhesus and Pigtail macaques* (Doctoral dissertation, Tulane University).
- Haynes, B. F., Moody, M. A., Alam, M., Bonsignori, M., Verkoczy, L., Ferrari, G., ... & Kelsoe, G. (2014). Progress in HIV-1 vaccine development. *Journal of Allergy and Clinical Immunology*; **134(1)**: 3-10.
- Hemelaar, J. (2013). Implications of HIV diversity for the HIV-1 pandemic. *Journal of Infection*; **66(5)**: 391-400.
- Hendricks, C. M., Cordeiro, T., Gomes, A. P., & Stevenson, M. (2021). The interplay of HIV-1 and macrophages in viral persistence. *Frontiers in Microbiology*; **12**: 646447.
- Herbein, G., & Varin, A. (2010). The macrophage in HIV-1 infection: from activation to deactivation. *Retrovirology*; **7**: 1-15.
- Himmel, D. M., & Arnold, E. (2020). Non-nucleoside reverse transcriptase inhibitors join forces with integrase inhibitors to combat HIV. *Pharmaceuticals*; **13(6)**: 122.

- Huang, L., & Crothers, K. (2009). HIV associated opportunistic pneumonia. *Respirology*; **14**(4): 474-485.
- Hull, M. W., Phillips, P., & Montaner, J. S. (2008). Changing global epidemiology of pulmonary manifestations of HIV/AIDS. *Chest*; **134**(6): 1287-1298.
- Irwin, A. C., Millen, J. V., & Fallows, D. (2003). *Global AIDS: myths and facts: tools for fighting the AIDS pandemic*. South End Press.
- Jiang, H., Zhou, Y., & Tang, W. (2020). Maintaining HIV care during the COVID-19 pandemic. *The Lancet HIV*; **7**(5): e308-e309.
- Jolley, E., Rhodes, T., Platt, L., Hope, V., Latypov, A., Donoghoe, M., & Wilson, D. (2012). HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with policy implications. *BMJ Open*; **2**(5): e001465.
- Kalamvoki, M. (2025). HSV-1 virions and related particles: biogenesis and implications in the infection. *Journal of Virology*: e01076-24.
- Katsa, M. M., & Yakubu, D. D. (2022). A Review of Potential Medicinal Plants in Prevention and Cure of Covid-19. *African Journal of Advances in Science and Technology Research*; **4**(1): 51-62.
- Kaur, A., & Vaccari, M. (2024). Exploring HIV vaccine progress in the pre-clinical and clinical setting: From history to prospects. *Viruses*; **16**(3): 368.
- Kedzierska, K., Crowe, S. M., Turville, S., & Cunningham, A. L. (2003). The influence of cytokines, chemokines, and their receptors on HIV 1 replication in monocytes and macrophages. *Reviews in Medical Virology*; **13**(1): 39-56.
- Keele, B.F., & Estes, J.D. (2011). Barriers to mucosal transmission of immunodeficiency viruses. *Blood, The Journal of the American Society of Hematology*; **118**(4): 839-846.
- Kerrigan, D., Sanchez Karver, T., Muraleetharan, O., Savage, V., Mbwambo, J., Donastorg, Y., ... & Barrington, C. (2020). A dream come true: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. *PLoS One*; **15**(6): e0234666.
- Kornfeld, H., & Cruikshank, W. W. (2001). Prospects for IL-16 in the treatment of AIDS. *Expert Opinion on Biological Therapy*; **1**(3): 425-432.
- Kruize, Z., & Kootstra, N. A. (2019). The role of macrophages in HIV-1 persistence and pathogenesis. *Frontiers in Microbiology*; **10**: 2828.
- Kumar, V., Prakash, O., Manpreet, S., Sumedh, G., & Medhi, B. (2006). Genetic basis of HIV-1 resistance and susceptibility: an approach to understanding the correlation between human genes and HIV-1 infection.
- Kurth, A. E., Celum, C., Baeten, J. M., Vermund, S. H., & Wasserheit, J. N. (2011). Combination HIV prevention: significance, challenges, and opportunities. *Current HIV/AIDS Reports*; **8**: 62-72.
- Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature*; **393**(6686): 648-659.
- Lama, J., & Planelles, V. (2007). Host factors influencing susceptibility to HIV infection and AIDS progression. *Retrovirology*; **4**: 1-25.
- Lewinski, M. K., & Bushman, F. D. (2005). Retroviral DNA integration mechanism and consequences. *Advances in Genetics*; **55**: 147-181.
- Liu, S., Abbondanzieri, E. A., Rausch, J. W., Grice, S. F. L., & Zhuang, X. (2008). Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. *Science*; **322**(5904): 1092-1097.
- Locher, C. P., Witt, S. A., Kassel, R., Dowell, N. L., Fujimura, S., & Levy, J. A. (2005). Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation. *Journal of General Virology*; **86**(4): 1171-1179.
- Lucas, M., Karrer, U. R. S., Lucas, A., & Klenerman, P. (2001). Viral escape mechanisms escapeology taught by viruses. *International Journal of Experimental Pathology*; **82**(5): 269-286.
- Mandal, A., Biswas, D., & Hazra, B. (2020). Natural products from plants with prospective anti-HIV activity and relevant

- mechanisms of action. *Studies in Natural Products Chemistry*; **66**: 225-271.
- Manna, S., Baidara, P., & Mandal, S. M. (2020). Molecular pathogenesis of secondary bacterial infection associated with viral infections including SARS-CoV-2. *Journal of Infection and Public Health*; **13(10)**: 1397-1404.
- McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019). CD8 T cell exhaustion during chronic viral infection and cancer. *Annual Review of Immunology*; **37(1)**: 457-495.
- Mohamed, H., Gurrola, T., Berman, R., Collins, M., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. (2022). Targeting CCR5 as a component of an HIV-1 therapeutic strategy. *Frontiers in Immunology*; **12**: 816515.
- Moretti, S., Schietroma, I., Sberna, G., Maggiorella, M. T., Sernicola, L., Farcomeni, S., ... & Borsetti, A. (2023). HIV-1 host interaction in gut-associated lymphoid tissue (GALT): effects on local environment and comorbidities. *International Journal of Molecular Sciences*; **24(15)**: 12193.
- Muema, D. M., Akilimali, N. A., Ndumnego, O. C., Rasehlo, S. S., Durgiah, R., Ojwach, D. B., ... & Ndung'u, T. (2020). Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection. *BMC Medicine*; **18**: 1-17.
- UNAIDS, C. B. O. (1995). Joint United Nations programme on HIV/AIDS (UNAIDS).
- Nash, D., Yotebieng, M., & Sohn, A. H. (2018). Treating all people living with HIV in sub-Saharan Africa: a new era calling for new approaches. *Journal of Virus Eradication*; **4**: 1-4.
- Nazziwa, J. (2022). *Dynamics of HIV-1 infection within and between hosts* (No. 2022: 93). Lund University.
- Obeagu, E. I. (2024). Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of Public Health*; **2(8)**: 44-55.
- Obeagu, E. I., & Obeagu, G. U. (2024). Preventive measures against HIV among Uganda's youth: Strategies, implementation, and effectiveness. *Medicine*; **103(44)**: e40317.
- Oguntibeju, O. O. (2012). Quality of life of people living with HIV and AIDS and antiretroviral therapy. *HIV/AIDS-Research and Palliative Care*: 117-124.
- Onwuliri, V. A., & Jolayemi, O. M. (2006). Reaching vulnerable and high-risk groups in Nigeria. Adeyi O, Kanki, PJ, Odutolu O, Idoko, editors. *AIDS in Nigeria: A nation on the threshold*. Cambridge: Harvard Center for Population and Development Studies: 309-322.
- Pandrea, I., Landay, A., Wilson, C., Stock, J., Tracy, R., & Apetrei, C. (2015). Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. *Current HIV/AIDS Reports*; **12**: 54-67.
- Panos, G., & Watson, D. C. (2015). Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors, overview of viral entry inhibition. *Critical Reviews in Microbiology*; **41(4)**: 473-487.
- Pasquereau, S., Kumar, A., & Herbein, G. (2017). Targeting TNF and TNF receptor pathway in HIV-1 infection: from immune activation to viral reservoirs. *Viruses*; **9(4)**: 64.
- Perelson, A. S. (1989). Modeling the interaction of the immune system with HIV. In *Mathematical and Statistical Approaches to AIDS Epidemiology*. Berlin, Heidelberg: Springer Berlin Heidelberg: 350-370.
- Poropatich, K., & Sullivan Jr, D. J. (2011). Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. *Journal of General Virology*; **92(2)**: 247-268.
- Prasad, S., & Tyagi, A. K. (2015). Curcumin and its analogues: a potential natural compound against HIV infection and AIDS. *Food & Function*; **6(11)**: 3412-3419.
- Ramjee, G., & Daniels, B. (2013). Women and HIV in sub-Saharan Africa. *AIDS Research And Therapy*; **10**: 1-9.
- Ran, X., Ao, Z., & Yao, X. (2016). Apobec3G-based strategies to defeat HIV infection. *Current HIV Research*; **14(3)**: 217-224.
- Rick, F., Odoke, W., van den Hombergh, J., Benzaken, A. S., & Avelino Silva, V. I. (2022). Impact of coronavirus disease (COVID 19) on HIV testing and care provision across four continents. *HIV*

- Medicine*; **23(2)**: 169-177.
- Righetto, R. C., Reis, R. K., Reinato, L. A. F., & Gir, E. (2014). Comorbidities and co-infections in people living with HIV/AIDS. *Rev Rene*; **15(6)**:942-948.
- Rogers, B. G., Paradis-Burnett, A., Nagel, K., Yolken, A., Strong, S. H., Arnold, T., ... & Chan, P. A. (2021). Sex workers and syndemics: A population vulnerable to HIV and COVID-19. *Archives of Sexual Behavior*; **50**: 2007-2016.
- Roy, A., Singh, A. K., Mishra, S., Chinnadurai, A., Mitra, A., & Bakshi, O. (2021). Mental health implications of the COVID-19 pandemic and its response in India. *International Journal of Social Psychiatry*; **67(5)**: 587-600.
- Safrit, J. T., Fast, P. E., Gieber, L., Kuipers, H., Dean, H. J., & Koff, W. C. (2016). Status of vaccine research and development of vaccines for HIV-1. *Vaccine*; **34(26)**: 2921-2925.
- Sanchez, T. H., Zlotorzynska, M., Rai, M., & Baral, S. D. (2020). Characterizing the impact of COVID-19 on men who have sex with men across the United States in April 2020. *AIDS and Behavior*; **24**: 2024-2032.
- Schols, D. (2004). HIV co-receptors as targets for antiviral therapy. *Current Topics in Medicinal Chemistry*; **4(9)**: 883-893.
- Sengupta, S., & Siliciano, R. F. (2018). Targeting the latent reservoir for HIV-1. *Immunity*; **48(5)**: 872-895.
- Sidebottom, D., Ekström, A. M., & Strömdahl, S. (2018). A systematic review of adherence to oral pre-exposure prophylaxis for HIV how can we improve uptake and adherence? *BMC Infectious Diseases*; **18(1)**: 1-14.
- Singh, A., Prasad, R., Balasubramanian, V., & Gupta, N. (2020). Drug-resistant tuberculosis and HIV infection: current perspectives. *HIV/AIDS-Research and Palliative Care*: 9-31.
- Sodora, D. L., & Silvestri, G. (2008). Immune activation and AIDS pathogenesis. *AIDS*; **22(4)**: 439-446.
- Tayal, V., & Kalra, B. S. (2008). Cytokines and anti-cytokines as therapeutics—An update. *European Journal of Pharmacology*; **579(1-3)**: 1-12.
- Ton, Q., & Frenkel, L. (2013). HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission. *Current HIV Research*; **11(2)**: 126-136.
- Toska, E., Laurenzi, C. A., Roberts, K. J., Cluver, L., & Sherr, L. (2020). Adolescent mothers affected by HIV and their children: a scoping review of evidence and experiences from sub-Saharan Africa. *Global Public Health*; **15(11)**: 1655-1673.
- Tse, L. V., Meganck, R. M., Graham, R. L., & Baric, R. S. (2020). The current and future state of vaccines, antivirals, and gene therapies against emerging coronaviruses. *Frontiers in Microbiology*; **11**: 658.
- Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024). Prophylactic and therapeutic vaccine development: advancements and challenges. *Molecular Biomedicine*; **5(1)**: 57.
- Wickham, C. H. (2019). *Transcriptional Analysis of the Host Response to HIV-1 Infection in CD4+ T Lymphocytes Monocytes and Macrophages* (Master's Thesis, University of Pretoria (South Africa)).
- World Health Organization Maximizing Positive Synergies Collaborative Group. (2009). An assessment of interactions between global health initiatives and country health systems. *The Lancet*; **373(9681)**: 2137-2169.
- World Health Organization. (2010). PMTCT strategic vision 2010-2015: preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals: moving towards the elimination of paediatric HIV, December 2009.
- World Health Organization. (2016). *Report on the WHO/TDR consultation on promoting implementation/operational research in countries receiving grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria: Domaine de Penthes, Geneva, Switzerland 9-10 December 2015*. World Health Organization: No. TDR/RCS/16.2.
- World Health Organization. (2022). *Consolidated guidelines on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations*. World Health Organization.
- Yandrapally, S., Mohareer, K., Arekuti, G.,

Vadankula, G. R., & Banerjee, S. (2021). HIV co-receptor-tropism: cellular and molecular events behind the enigmatic co-receptor switching. *Critical Reviews in Microbiology*; **47(4)**: 499-516.

Zhou, S., Long, N., & Swanstrom, R. (2023). Evolution driven by a varying host environment selects for distinct HIV-1 entry

phenotypes and other informative variants. *Frontiers in Virology*; **3**: 1291996.

Zirafi, O., Kim, K. A., Ständker, L., Mohr, K. B., Sauter, D., Heigele, A., ... & Münch, J. (2015). Discovery and characterization of an endogenous CXCR4 antagonist. *Cell Reports*; **11(5)**: 737-747.

**Citation:** Abraham Ehinomhen Ubhenin, Joshua Onyeka Ikebuiro, Yusuf Nafisat Abdulmalik, Tyem Lawal Danjuma. Unravelling HIV-1's Immune Evasion: Insights into Persistent Infection, Disease Progression, and Emerging Therapies. *Sokoto Journal of Medical Laboratory Science*; **10(1)**: 253 – 270. <https://dx.doi.org/10.4314/sokjmls.v10i1.27>

**Copyright:** This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.